RA306 and RA608, two other ATP-competitive CaMKII inhibitors, have been shown to ameliorate cardiac function in vivo in a mouse model of dilated cardiomyopathy and in afterload-induced heart failure, respectively, overcoming the limited bioavailability of previous CaMKII inhibitors [54,55]. Here, CAMK2G is linked to dilated cardiomyopathy.